{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:06:29Z","timestamp":1790856389312,"version":"4.1.0"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["GAP2145"],"award-info":[{"award-number":["GAP2145"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.bcp.2022.114929","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T15:03:15Z","timestamp":1642604595000},"page":"114929","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Phytochemicals targeting JAK\/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?"],"prefix":"10.1016","volume":"197","author":[{"given":"Gurleen","family":"Kour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupali","family":"Choudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobia","family":"Anjum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asha","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bijender Kumar","family":"Bajaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabeer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0010","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1084\/jem.20160792","article-title":"Historical observations contributing insights on etiopathogenesis of rheumatoid arthritis and role of rheumatoid factor","volume":"213","author":"Tan","year":"2016","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.bcp.2022.114929_b0015","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990\u20132017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/nri.2016.124","article-title":"The immunopathogenesis of seropositive rheumatoid arthritis: from triggering to targeting","volume":"17","author":"Malmstr\u00f6m","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bcp.2022.114929_b0025","first-page":"30173","article-title":"Therapies for bone R","author":"Smolen","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0030","doi-asserted-by":"crossref","DOI":"10.1186\/s41232-020-00133-8","article-title":"Rheumatoid arthritis","volume":"40","author":"Tanaka","year":"2020","journal-title":"Inflamm. Regenerat."},{"issue":"13","key":"10.1016\/j.bcp.2022.114929_b0035","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1001\/jama.2018.13103","article-title":"Diagnosis and management of rheumatoid arthritis: a review","volume":"320","author":"Aletaha","year":"2018","journal-title":"JAMA"},{"issue":"10086","key":"10.1016\/j.bcp.2022.114929_b0040","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(17)31491-5","article-title":"Novel treatment strategies in rheumatoid arthritis","volume":"389","author":"Burmester","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0045","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3390\/cells9040880","article-title":"Update on the pathomechanism, diagnosis, and treatment options for rheumatoid arthritis","volume":"9","author":"Lin","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3280","article-title":"Biochemical markers of ongoing joint damage in rheumatoid arthritis-current and future applications, limitations and opportunities","volume":"13","author":"Karsdal","year":"2011","journal-title":"Arthritis Res. Therapy"},{"issue":"9","key":"10.1016\/j.bcp.2022.114929_b0055","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res."},{"issue":"5 Suppl 101","key":"10.1016\/j.bcp.2022.114929_b0065","first-page":"S40","article-title":"The Disease Activity Score (DAS) and the Disease Activity Score using 28 joint counts (DAS28) in the management of rheumatoid arthritis","volume":"34","author":"Van Riel","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0070","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: current status and future studies","volume":"6","author":"Hua","year":"2020","journal-title":"RMD open"},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0075","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","article-title":"Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)","volume":"72","author":"Buttgereit","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0080","doi-asserted-by":"crossref","first-page":"e000134","DOI":"10.1136\/rmdopen-2015-000134","article-title":"Delayed-release prednisone improves fatigue and health-related quality of life: findings from the CAPRA-2 double-blind randomised study in rheumatoid arthritis","volume":"1","author":"Alten","year":"2015","journal-title":"RMD open"},{"key":"10.1016\/j.bcp.2022.114929_b0085","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-020-04547-y","article-title":"Methotrexate-related toxicity in patients with rheumatoid arthritis and renal dysfunction","volume":"40","author":"Lee","year":"2020","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bcp.2022.114929_b0095","first-page":"53","article-title":"Reappraisal of the clinical use of leflunomide in rheumatoid arthritis and psoriatic arthritis","volume":"2","author":"Jones","year":"2010","journal-title":"Open Access Rheumatol. Res. Rev."},{"issue":"7","key":"10.1016\/j.bcp.2022.114929_b0100","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keh191","article-title":"Peripheral neuropathy in patients on leflunomide","volume":"43","author":"Bharadwaj","year":"2004","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0105","doi-asserted-by":"crossref","first-page":"345","DOI":"10.2165\/00002018-200427050-00006","article-title":"Leflunomide for the treatment of rheumatoid arthritis in clinical practice","volume":"27","author":"van Roon","year":"2004","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0110","doi-asserted-by":"crossref","first-page":"R232","DOI":"10.1186\/ar4075","article-title":"Leflunomide increases the risk of silent liver fibrosis in patients with rheumatoid arthritis receiving methotrexate","volume":"14","author":"Lee","year":"2012","journal-title":"Arthritis Res. Therapy"},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0115","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3109\/03009742.2013.785590","article-title":"Leflunomide discontinuation in rheumatoid arthritis and influence of associated disease-modifying anti-rheumatic drugs: a survival analysis","volume":"42","author":"Rodriguez-Rodriguez","year":"2013","journal-title":"Scand. J. Rheumatol."},{"issue":"01","key":"10.1016\/j.bcp.2022.114929_b0120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2022.114929_b0125","article-title":"FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide)","volume":"13","author":"Fda","year":"2010","journal-title":"US FDA"},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0130","first-page":"762","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Care Res. Official J. American College Rheumatol."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0135","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/rheumatology\/36.10.1089","article-title":"Predisposing factors in sulphasalazine-induced systemic lupus erythematosus","volume":"36","author":"Gunnarsson","year":"1997","journal-title":"Br. J. Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0140","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-60467-8","article-title":"The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis","volume":"10","author":"Yee","year":"2020","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1517\/14740338.2011.529898","article-title":"Oxidative stress as a mechanism underlying sulfasalazine-induced toxicity","volume":"10","author":"Linares","year":"2011","journal-title":"Expert Opin. Drug Safety"},{"key":"10.1016\/j.bcp.2022.114929_b0150","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bpobgyn.2019.09.004","article-title":"Paternal safety of anti-rheumatic medications","volume":"64","author":"Bermas","year":"2020","journal-title":"Best Pract. Res. Clin. Obstet. Gynaecol."},{"issue":"11","key":"10.1016\/j.bcp.2022.114929_b0155","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.3899\/jrheum.170158","article-title":"Risk of retinal toxicity in longterm users of hydroxychloroquine","volume":"44","author":"Kim","year":"2017","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0160","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/art.30129","article-title":"American College of Rheumatology\/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials","volume":"63","author":"Felson","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheumatol. Therapy"},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0170","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/annrheumdis-2016-210713","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"76","author":"Nam","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.bcp.2022.114929_b0175","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0180","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/acr.21928","article-title":"Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study","volume":"65","author":"Veetil","year":"2013","journal-title":"Arthritis Care Res."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/BOR.0b013e3282fb03d8","article-title":"Biologics and heart failure in rheumatoid arthritis: are we any wiser?","volume":"20","author":"Danila","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"key":"10.1016\/j.bcp.2022.114929_b0190","doi-asserted-by":"crossref","first-page":"384","DOI":"10.3389\/fimmu.2015.00384","article-title":"T cell migration in rheumatoid arthritis","volume":"6","author":"Mellado","year":"2015","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.bcp.2022.114929_b0195","first-page":"2134","article-title":"Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies","volume":"54","author":"Cavalli","year":"2015","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0200","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","article-title":"Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event","volume":"24","author":"Berger","year":"2018","journal-title":"J. Neurovirol."},{"issue":"7","key":"10.1016\/j.bcp.2022.114929_b0205","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/1744666X.2017.1259068","article-title":"Improving B-cell depletion in systemic lupus erythematosus and rheumatoid arthritis","volume":"13","author":"Mota","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0210","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheumat. Off. J. American College Rheumatol."},{"issue":"9990","key":"10.1016\/j.bcp.2022.114929_b0215","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2022.114929_b0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.cbpa.2016.03.006","article-title":"Janus kinase inhibitors for rheumatoid arthritis","volume":"32","author":"Yamaoka","year":"2016","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","article-title":"Mechanisms and consequences of Jak\u2013STAT signaling in the immune system","volume":"18","author":"Villarino","year":"2017","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0230","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/art.39953","article-title":"Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment","volume":"69","author":"Fleischmann","year":"2017","journal-title":"Arthritis Rheumatol."},{"issue":"Supplement_1","key":"10.1016\/j.bcp.2022.114929_b0235","doi-asserted-by":"crossref","first-page":"i17","DOI":"10.1093\/rheumatology\/key225","article-title":"Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Taylor","year":"2019","journal-title":"Rheumatology"},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0240","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The emerging safety profile of JAK inhibitors in rheumatic disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"issue":"25","key":"10.1016\/j.bcp.2022.114929_b0245","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-019-1866-2","article-title":"Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study","volume":"21","author":"Wollenhaupt","year":"2019","journal-title":"Arthritis Res. Therapy"},{"issue":"9","key":"10.1016\/j.bcp.2022.114929_b0255","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1177\/1060028019839650","article-title":"Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis","volume":"53","author":"Mogul","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"8","key":"10.1016\/j.bcp.2022.114929_b0260","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","article-title":"Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials","volume":"78","author":"Xie","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0265","doi-asserted-by":"crossref","DOI":"10.1186\/s41927-018-0031-x","article-title":"In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol."},{"issue":"10139","key":"10.1016\/j.bcp.2022.114929_b0270","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0275","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.bcp.2022.114929_b0280","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.1016\/j.bmc.2018.08.005","article-title":"Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor","volume":"26","author":"Hamaguchi","year":"2018","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0285","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1136\/annrheumdis-2019-215164","article-title":"Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan","volume":"78","author":"Takeuchi","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0290","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0295","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/art.39463","article-title":"Decernotinib: a next-generation Jakinib","volume":"68","author":"Gadina","year":"2016","journal-title":"Arthritis Rheumatol. (Hoboken, NJ)"},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0300","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1136\/annrheumdis-2018-213289","article-title":"Inequity in access to bDMARD care and how it influences disease outcomes across countries worldwide: results from the METEOR-registry","volume":"77","author":"Bergstra","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0305","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.coph.2007.03.002","article-title":"Natural products as a gold mine for arthritis treatment","volume":"7","author":"Khanna","year":"2007","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107452","article-title":"Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony","volume":"207","author":"Zhang","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2022.114929_b0315","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s00296-011-1841-y","article-title":"A Chinese herb Tripterygium wilfordii Hook F in the treatment of rheumatoid arthritis: mechanism, efficacy, and safety","volume":"31","author":"Bao","year":"2011","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bcp.2022.114929_b0320","doi-asserted-by":"crossref","first-page":"105618","DOI":"10.1016\/j.phrs.2021.105618","article-title":"Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends","volume":"169","author":"Kour","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2022.114929_b0325","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jep.2017.03.022","article-title":"A review of the ethnopharmacology, phytochemistry and pharmacology of Notopterygium incisum","volume":"202","author":"Azietaku","year":"2017","journal-title":"J. Ethnopharmacol."},{"issue":"01","key":"10.1016\/j.bcp.2022.114929_b0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1055\/s-0029-1185971","article-title":"Antiproliferative and apoptotic activities of linear furocoumarins from Notopterygium incisum on cancer cell lines","volume":"76","author":"Wu","year":"2010","journal-title":"Planta Med."},{"key":"10.1016\/j.bcp.2022.114929_b0335","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2147\/DDDT.S189969","article-title":"Notopterol-induced apoptosis and differentiation in human acute myeloid leukemia HL-60 cells","volume":"13","author":"Huang","year":"2019","journal-title":"Drug Des. Development Therapy"},{"issue":"11","key":"10.1016\/j.bcp.2022.114929_b0340","doi-asserted-by":"crossref","first-page":"108158","DOI":"10.1016\/j.celrep.2020.108158","article-title":"The Natural Compound Notopterol Binds and Targets JAK2\/3 to Ameliorate Inflammation and Arthritis","volume":"32","author":"Wang","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.bcp.2022.114929_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106384","article-title":"Anti-rheumatoid arthritis effects of flavonoids from Daphne genkwa","volume":"83","author":"Sun","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0350","doi-asserted-by":"crossref","unstructured":"Gao, Y., et al., Genkwanin inhibits proinflammatory mediators mainly through the regulation of miR-101\/MKP-1\/MAPK pathway in LPS-activated macrophages. Plos one, 2014. 9(5): p. e96741.","DOI":"10.1371\/journal.pone.0096741"},{"key":"10.1016\/j.bcp.2022.114929_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2019.153036","article-title":"Genkwanin ameliorates adjuvant-induced arthritis in rats through inhibiting JAK\/STAT and NF-\u03baB signaling pathways","volume":"63","author":"Bao","year":"2019","journal-title":"Phytomedicine"},{"issue":"12","key":"10.1016\/j.bcp.2022.114929_b0360","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1016\/j.bcp.2011.07.093","article-title":"Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications","volume":"82","author":"Singh","year":"2011","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0365","first-page":"317","article-title":"Epigallocatechin 3-gallate attenuates arthritis by regulating Nrf2, HO-1, and cytokine levels in an experimental arthritis model","volume":"67","author":"Karatas","year":"2020","journal-title":"Biotechnol. Appl. Biochem."},{"issue":"1-3","key":"10.1016\/j.bcp.2022.114929_b0370","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ejphar.2012.06.026","article-title":"Pro-apoptotic effect of epigallo-catechin-3-gallate on B lymphocytes through regulating BAFF\/PI3K\/Akt\/mTOR signaling in rats with collagen-induced arthritis","volume":"690","author":"Liu","year":"2012","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0375","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s10753-012-9457-2","article-title":"A novel combination of methotrexate and epigallocatechin attenuates the overexpression of pro-inflammatory cartilage cytokines and modulates antioxidant status in adjuvant arthritic rats","volume":"35","author":"Roy","year":"2012","journal-title":"Inflammation"},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0380","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1189\/jlb.3A0514-261RR","article-title":"Epigallocatechin-3-gallate ameliorates autoimmune arthritis by reciprocal regulation of T helper-17 regulatory T cells and inhibition of osteoclastogenesis by inhibiting STAT3 signaling","volume":"100","author":"Lee","year":"2016","journal-title":"J. Leukoc. Biol."},{"issue":"7","key":"10.1016\/j.bcp.2022.114929_b0385","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.3390\/antiox10071044","article-title":"Olive Polyphenols: Antioxidant and Anti-Inflammatory Properties","volume":"10","author":"Bucciantini","year":"2021","journal-title":"Antioxidants"},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0390","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2013.10.017","article-title":"Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKC\u03b1 and PKC\u03b21 inhibition","volume":"232","author":"Scoditti","year":"2014","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.bcp.2022.114929_b0395","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.3390\/molecules23123212","article-title":"Hydroxytyrosol exerts anti-inflammatory and anti-oxidant activities in a mouse model of systemic inflammation","volume":"23","author":"Fuccelli","year":"2018","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.bcp.2022.114929_b0400","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/mnfr.201500304","article-title":"Preventive effects of dietary hydroxytyrosol acetate, an extra virgin olive oil polyphenol in murine collagen-induced arthritis","volume":"59","author":"Rosillo","year":"2015","journal-title":"Mol. Nutr. Food Res."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0405","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/nu11050946","article-title":"Influence of resveratrol on the immune response","volume":"11","author":"Malaguarnera","year":"2019","journal-title":"Nutrients"},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/biof.1599","article-title":"Resveratrol ameliorates rheumatoid arthritis via activation of SIRT1-Nrf2 signaling pathway","volume":"46","author":"Wang","year":"2020","journal-title":"BioFactors"},{"issue":"8","key":"10.1016\/j.bcp.2022.114929_b0415","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1007\/s10067-018-4080-8","article-title":"Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study","volume":"37","author":"Khojah","year":"2018","journal-title":"Clin. Rheumatol."},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0420","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/abbs\/gmu135","article-title":"Anti-inflammatory effect of resveratrol through the suppression of NF-\u03baB and JAK\/STAT signaling pathways","volume":"47","author":"Ma","year":"2015","journal-title":"Acta Biochim. Biophy. Sin."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0425","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.jnutbio.2010.07.012","article-title":"Resveratrol down-regulates interferon-\u03b3-inducible inflammatory genes in macrophages: molecular mechanism via decreased STAT-1 activation","volume":"22","author":"Chung","year":"2011","journal-title":"The Journal of nutritional biochemistry"},{"key":"10.1016\/j.bcp.2022.114929_b0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.111039","article-title":"A mechanistic insight of phytoestrogens used for Rheumatoid arthritis: An evidence-based review","volume":"133","author":"Chakraborty","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2022.114929_b0435","doi-asserted-by":"crossref","unstructured":"Yoon, H.Y., et al., Kaempferol inhibits IL\u20111\u03b2\u2011induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX\u20112, PGE2 and MMPs. International journal of molecular medicine, 2013. 32(4): p. 971-977.","DOI":"10.3892\/ijmm.2013.1468"},{"key":"10.1016\/j.bcp.2022.114929_b0440","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jff.2016.09.003","article-title":"Protective effect of kaempferol, a flavonoid widely present in varieties of edible plants, on IL-1\u03b2-induced inflammatory response via inhibiting MAPK, Akt, and NF-\u03baB signalling in SW982 cells","volume":"27","author":"Lian","year":"2016","journal-title":"J. Funct. Foods"},{"key":"10.1016\/j.bcp.2022.114929_b0445","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.intimp.2017.12.011","article-title":"Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway","volume":"55","author":"Pan","year":"2018","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0450","first-page":"54","article-title":"STAT3 and NF-\u03baB are common targets for kaempferol-mediated attenuation of COX-2 expression in IL-6-induced macrophages and carrageenan-induced mouse paw edema","volume":"12","author":"Basu","year":"2017","journal-title":"Biochem. Biophys. Rep."},{"key":"10.1016\/j.bcp.2022.114929_b0455","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cbi.2018.02.022","article-title":"Kaempferol 7-O-\u03b2-D-glucoside isolated from the leaves of Cudrania tricuspidata inhibits LPS-induced expression of pro-inflammatory mediators through inactivation of NF-\u03baB, AP-1, and JAK-STAT in RAW 264.7 macrophages","volume":"284","author":"Lee","year":"2018","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.bcp.2022.114929_b0460","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s10067-012-2148-4","article-title":"Genistein: the potential for efficacy in rheumatoid arthritis","volume":"32","author":"Li","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.bcp.2022.114929_b0465","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/DDDT.S52354","article-title":"Genistein suppresses tumor necrosis factor \u03b1-induced inflammation via modulating reactive oxygen species\/Akt\/nuclear factor \u03baB and adenosine monophosphate-activated protein kinase signal pathways in human synoviocyte MH7A cells","volume":"8","author":"Li","year":"2014","journal-title":"Drug Des. Development Therapy"},{"key":"10.1016\/j.bcp.2022.114929_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106387","article-title":"Phytoestrogens protect joints in collagen induced arthritis by increasing IgG glycosylation and reducing osteoclast activation","volume":"83","author":"Du","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0475","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s10753-011-9365-x","article-title":"Genistein inhibit cytokines or growth factor-induced proliferation and transformation phenotype in fibroblast-like synoviocytes of rheumatoid arthritis","volume":"35","author":"Zhang","year":"2012","journal-title":"Inflammation"},{"key":"10.1016\/j.bcp.2022.114929_b0480","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jot.2019.07.007","article-title":"Genistein inhibits angiogenesis developed during rheumatoid arthritis through the IL-6\/JAK2\/STAT3\/VEGF signalling pathway","volume":"22","author":"Cheng","year":"2020","journal-title":"J. Orthopaedic Translat."},{"key":"10.1016\/j.bcp.2022.114929_b0485","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.biopha.2017.10.064","article-title":"Chlorogenic acid (CGA): A pharmacological review and call for further research","volume":"97","author":"Naveed","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0490","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00011-013-0674-4","article-title":"Anti-inflammatory effects of chlorogenic acid in lipopolysaccharide-stimulated RAW 264.7 cells","volume":"63","author":"Hwang","year":"2014","journal-title":"Inflamm. Res."},{"issue":"8","key":"10.1016\/j.bcp.2022.114929_b0495","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/ptr.3684","article-title":"Differential effects of chlorogenic acid on various immunological parameters relevant to rheumatoid arthritis","volume":"26","author":"Chauhan","year":"2012","journal-title":"Phytother. Res."},{"key":"10.1016\/j.bcp.2022.114929_b0500","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cbi.2017.05.002","article-title":"Protective effect of Chlorogenic acid against methotrexate induced oxidative stress, inflammation and apoptosis in rat liver: An experimental approach","volume":"272","author":"Ali","year":"2017","journal-title":"Chem. Biol. Interact."},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0505","doi-asserted-by":"crossref","first-page":"499","DOI":"10.3109\/08923973.2015.1095763","article-title":"Chlorogenic acid and luteolin synergistically inhibit the proliferation of interleukin-1 \u03b2-induced fibroblast-like synoviocytes through regulating the activation of NF-\u03ba B and JAK\/STAT-signaling pathways","volume":"37","author":"Lou","year":"2015","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.bcp.2022.114929_b0510","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.2147\/DDDT.S299753","article-title":"Chemistry, Pharmacology and Therapeutic Potential of Swertiamarin\u2013A Promising Natural Lead for New Drug Discovery and Development","volume":"15","author":"Fadzil","year":"2021","journal-title":"Drug design, development and therapy"},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0515","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00011-014-0717-5","article-title":"Swertiamarin ameliorates inflammation and osteoclastogenesis intermediates in IL-1\u03b2 induced rat fibroblast-like synoviocytes","volume":"63","author":"Saravanan","year":"2014","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.bcp.2022.114929_b0520","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejps.2014.02.005","article-title":"Swertiamarin attenuates inflammation mediators via modulating NF-\u03baB\/I \u03baB and JAK2\/STAT3 transcription factors in adjuvant induced arthritis","volume":"56","author":"Saravanan","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0525","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/nu9101089","article-title":"Dietary anthocyanins against obesity and inflammation","volume":"9","author":"Lee","year":"2017","journal-title":"Nutrients"},{"issue":"4","key":"10.1016\/j.bcp.2022.114929_b0530","first-page":"382","article-title":"Bioavailability, antioxidant and biological properties of the natural free-radical scavengers cyanidin and related glycosides","volume":"43","author":"Galvano","year":"2007","journal-title":"Annali dell'Istituto superiore di sanita"},{"issue":"3","key":"10.1016\/j.bcp.2022.114929_b0535","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/jcp.24916","article-title":"Dual effect of cyanidin on RANKL-induced differentiation and fusion of osteoclasts","volume":"231","author":"Dou","year":"2016","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.bcp.2022.114929_b0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114917","article-title":"Cyanidin prevents the hyperproliferative potential of fibroblast-like synoviocytes and disease progression via targeting IL-17A cytokine signalling in rheumatoid arthritis","volume":"391","author":"Samarpita","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0545","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.btre.2014.09.002","article-title":"Potential applications of ferulic acid from natural sources","volume":"4","author":"Kumar","year":"2014","journal-title":"Biotechnol. Rep,"},{"key":"10.1016\/j.bcp.2022.114929_b0550","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.lfs.2018.06.013","article-title":"Ferulic acid, a dietary polyphenol suppresses osteoclast differentiation and bone erosion via the inhibition of RANKL dependent NF-\u03baB signalling pathway","volume":"207","author":"Doss","year":"2018","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0555","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1002\/jcb.27502","article-title":"Ferulic acid inhibits interleukin 17-dependent expression of nodal pathogenic mediators in fibroblast-like synoviocytes of rheumatoid arthritis","volume":"120","author":"Ganesan","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0560","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10787-019-00642-0","article-title":"Anti-arthritic activity of ferulic acid in complete Freund\u2019s adjuvant (CFA)-induced arthritis in rats: JAK2 inhibition","volume":"28","author":"Zhu","year":"2020","journal-title":"Inflammopharmacology"},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0565","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/01635581.2020.1749676","article-title":"Therapeutic effects of curcumol in several diseases: An overview","volume":"73","author":"Hashem","year":"2021","journal-title":"Nutrition Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0570","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.bbrc.2014.04.009","article-title":"Curcumol suppresses RANKL-induced osteoclast formation by attenuating the JNK signaling pathway","volume":"447","author":"Yu","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2022.114929_b0575","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ejphar.2013.11.007","article-title":"Curcumol exhibits anti-inflammatory properties by interfering with the JNK-mediated AP-1 pathway in lipopolysaccharide-activated RAW264. 7 cells","volume":"723","author":"Chen","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0580","first-page":"1","article-title":"Inhibitory effect of curcumol on Jak2-STAT signal pathway molecules of fibroblast-like synoviocytes in patients with rheumatoid arthritis","volume":"2012","author":"Wang","year":"2012","journal-title":"Evidence-Based Complementary Alternative Med."},{"issue":"10","key":"10.1016\/j.bcp.2022.114929_b0585","doi-asserted-by":"crossref","first-page":"8833","DOI":"10.3390\/molecules16108833","article-title":"Components of rhizome extract of Cnidium officinale Makino and their in vitro biological effects","volume":"16","author":"Bae","year":"2011","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0590","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/sj.bjp.0706022","article-title":"Falcarindiol impairs the expression of inducible nitric oxide synthase by abrogating the activation of IKK and JAK in rat primary astrocytes","volume":"144","author":"Shiao","year":"2005","journal-title":"Br. J. Pharmacol."},{"issue":"1-2","key":"10.1016\/j.bcp.2022.114929_b0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11010-017-3262-z","article-title":"Falcarindiol inhibits LPS-induced inflammation via attenuating MAPK and JAK-STAT signaling pathways in murine macrophage RAW 264.7 cells","volume":"445","author":"Venkatesan","year":"2018","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bcp.2022.114929_b0600","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/j.biopha.2017.07.068","article-title":"Baicalein: A review of its anti-cancer effects and mechanisms in Hepatocellular Carcinoma","volume":"93","author":"Bie","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2022.114929_b0605","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2018.9054","article-title":"Therapeutic effect of the natural compounds baicalein and baicalin on autoimmune diseases","author":"Xu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bcp.2022.114929_b0610","first-page":"1","article-title":"Anti-inflammatory activities of Cinnamomum cassia constituents in vitro and in vivo","volume":"2012","author":"Liao","year":"2012","journal-title":"Evidence-Based Complementary and Alternative Medicine"},{"key":"10.1016\/j.bcp.2022.114929_b0615","first-page":"1","article-title":"Regulatory effect of cinnamaldehyde on monocyte\/macrophage-mediated inflammatory responses","volume":"2010","author":"Kim","year":"2010","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.bcp.2022.114929_b0620","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejphar.2019.02.031","article-title":"Anti-oxidant and anti-inflammatory effects of cinnamaldehyde and eugenol on mononuclear cells of rheumatoid arthritis patients","volume":"852","author":"Mateen","year":"2019","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0625","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1124\/jpet.119.262907","article-title":"Cinnamaldehyde inhibits inflammation of human synoviocyte cells through regulation of Jak\/Stat pathway and ameliorates collagen-induced arthritis in rats","volume":"373","author":"Cheng","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.bcp.2022.114929_b0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111332","article-title":"A review of the biological activity and pharmacology of cryptotanshinone, an important active constituent in Danshen","volume":"137","author":"Li","year":"2021","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bcp.2022.114929_b0635","first-page":"1067","article-title":"Cryptotanshinone induces reactive oxygen species-mediated apoptosis in human rheumatoid arthritis fibroblast-like synoviocytes","volume":"43","author":"Sun","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.bcp.2022.114929_b0640","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bcp.2017.05.006","article-title":"Therapeutic effect of Cryptotanshinone on experimental rheumatoid arthritis through downregulating p300 mediated-STAT3 acetylation","volume":"138","author":"Wang","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0645","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fphar.2018.00104","article-title":"A mechanistic overview of triptolide and celastrol, natural products from Tripterygium wilfordii Hook F","volume":"9","author":"Chen","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bcp.2022.114929_b0650","doi-asserted-by":"crossref","unstructured":"Kong, X., et al., Anti-angiogenic effect of triptolide in rheumatoid arthritis by targeting angiogenic cascade. PLoS One, 2013. 8(10): p. e77513.","DOI":"10.1371\/journal.pone.0077513"},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0655","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s11596-020-2302-1","article-title":"Triptolide Inhibits Expression of Inflammatory Cytokines and Proliferation of Fibroblast-like Synoviocytes Induced by IL-6\/sIL-6R-Mediated JAK2\/STAT3 Signaling Pathway","volume":"41","author":"Lin","year":"2021","journal-title":"Current Med. Sci."},{"key":"10.1016\/j.bcp.2022.114929_b0660","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fnut.2017.00052","article-title":"Managing rheumatoid arthritis with dietary interventions","volume":"4","author":"Khanna","year":"2017","journal-title":"Front. Nutrit."},{"issue":"24","key":"10.1016\/j.bcp.2022.114929_b0665","doi-asserted-by":"crossref","first-page":"14285","DOI":"10.1039\/D1RA01491A","article-title":"Hyaluronic acid\u2013green tea catechin conjugates as a potential therapeutic agent for rheumatoid arthritis","volume":"11","author":"Lee","year":"2021","journal-title":"RSC Adv."},{"issue":"1","key":"10.1016\/j.bcp.2022.114929_b0670","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/13880209.2019.1699123","article-title":"Preparation of resveratrol dry suspension and its immunomodulatory and anti-inflammatory activity in mice","volume":"58","author":"Chen","year":"2020","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.bcp.2022.114929_b0675","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ejps.2015.07.012","article-title":"A novel approach to arthritis treatment based on resveratrol and curcumin co-encapsulated in lipid-core nanocapsules: In vivo studies","volume":"78","author":"Coradini","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2022.114929_b0680","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118560","article-title":"Development and evaluation of PLA-coated co-micellar nanosystem of Resveratrol for the intra-articular treatment of arthritis","volume":"569","author":"Kamel","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.bcp.2022.114929_b0685","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ejps.2017.01.011","article-title":"Characterization, pharmacokinetics and tissue distribution of chlorogenic acid-loaded self-microemulsifying drug delivery system","volume":"100","author":"Chen","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.bcp.2022.114929_b0690","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108622","article-title":"Quercetin loaded nanoemulsion-based gel for rheumatoid arthritis: In vivo and in vitro studies","volume":"112","author":"Gokhale","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.bcp.2022.114929_b0695","first-page":"2663","article-title":"Fabrication of novel vesicles of triptolide for antirheumatoid activity with reduced toxicity in vitro and in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"Int. J. Nanomed."},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0700","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.apsb.2015.09.006","article-title":"Pharmacokinetic and pharmacodynamic study of triptolide-loaded liposome hydrogel patch under microneedles on rats with collagen-induced arthritis","volume":"5","author":"Chen","year":"2015","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"6","key":"10.1016\/j.bcp.2022.114929_b0705","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann. Rheum. Dis."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295222000235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:35:42Z","timestamp":1757770542000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295222000235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":141,"alternative-id":["S0006295222000235"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114929","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phytochemicals targeting JAK\/STAT pathway in the treatment of rheumatoid arthritis: Is there a future?","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2022.114929","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114929"}}